ProTgen was founded by Juan Carlos Zuniga-Pflucker in 2023.

Who are ProTgen's investors?

ProTgen's investors include Eisai Innovation, Inc., FACIT (Fight Against Cancer Innovation Trust).

How much funding has ProTgen raised?

ProTgen has disclosed $8.2M raised across 1 round.

Where is ProTgen headquartered?

ProTgen is headquartered in Toronto.

ProTgen

Toronto · Founded 2023 · 2 known investors

protgen.bio ↗

ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).

BiotechHealthtech

Founders & leadership

ProTgen was founded in 2023 by Juan Carlos Zuniga-Pflucker.

Juan Carlos Zuniga-PfluckerFounder

Board

Fei ShenBoard director

Ferdinand MassariBoard director

Investors · 2

Eisai Innovation, Inc.San Francisco

FACIT (Fight Against Cancer Innovation Trust)Toronto · $1.1M

Reported raises · per SEC filings

Form D private placements

$8.2M disclosed across 1 round · 2024

▶$8.2MraisedDec 2024 · 4 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Fei ShenDirector
Juan Carlos Zuniga-PfluckerExecutive Officer, Director
Ferdinand MassariDirector

Offering amount: $20M
Amount sold: $8.2M
First sale: Nov 2024
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

PepGen3 shared keywordsPepGen develops disease-modifying therapeutics aimed at the underlying causes of serious genetic neuromuscular and neurological diseases. The company is building a pipeline of oligonucleotide-based treatments for these conditions.

Companies competing with ProTgen for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does ProTgen do?: ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).
Who founded ProTgen?: ProTgen was founded by Juan Carlos Zuniga-Pflucker in 2023.
Who are ProTgen's investors?: ProTgen's investors include Eisai Innovation, Inc., FACIT (Fight Against Cancer Innovation Trust).
How much funding has ProTgen raised?: ProTgen has disclosed $8.2M raised across 1 round.
Where is ProTgen headquartered?: ProTgen is headquartered in Toronto.